Cypress and Forest Labs' Savella to go on sales in the USA on April 28

US drugmakers Forest Laboratories and Cypress Bioscience say that Savella (milnacipran HCl), their co-developed selective serotonin and  norepinephrine dual reuptake inhibitor approved for the management of  fibromyalgia, will be shipped to wholesalers on April 24 and will be  available at pharmacies beginning on April 28. After Savella was  approved by US regulators at the start of the year (Marketletter January  26), the companies submitted a minor post-approval cosmetic formulation  change which has now been approved. The agent is a potential  blockbuster with key differentiating characteristics as a treatment  for this chronic condition, which affects as many as six million people  in the USA. Its safety and efficacy was established in late-stage trials  involving over 2,000 patients.